NCT00161213View on ClinicalTrials.gov

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

imatinib mesylate

Trial Locations (8)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

07728

CentraState Medical Center, Freehold

08690

Cancer Institute of New Jersey at Hamilton, Hamilton

07754

Jersey Shore Cancer Center at Jersey Shore University Medical Center, Neptune City

08901

Central Jersey Oncology Group, New Brunswick

08903

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick

Saint Peter's University Hospital, New Brunswick

07103

New Jersey Medical School, Newark

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT00161213 - Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter